An interventional study of surgical aortic valve replacement and Transcatheter aortic valve replacement in Aortic Stenosis, sponsored by Osaka University. Recruiting at 37 sites in Japan. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Osaka University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Aortic Valve Stenosis with a site in Japan — 4 open to participants now, 7 under way, none of them phase 3. Aortic Valve Stenosis · Japan.
Among the 19 studies in Aortic Valve Stenosis with a site in Japan, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, and was the 18th registered.
1,027 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →4 of the 19 studies in Aortic Valve Stenosis with a site in Japan are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Japan
Ages 18–100
OCEAN-SHD Study Group · Sites in Japan
Ages 20+
Edwards Lifesciences · Sites in Japan, United States, Australia and 3 more countries
Ages 65+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 64 across the 15 interventional studies, 803 across the 4 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 19 have an industry lead sponsor. The 10 most frequent:
Osaka University is the lead sponsor of 34 studies on the registry; 4 are open to participants now.
Osaka University has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Stenosis with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06007222OCEAN-SHD Study GroupNon-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Aortic Valve Stenosis with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To establish the safety and effectiveness of surgical aortic valve replacement (SAVR) in patients with isolated severe, calcific aortic stenosis who are at low surgical risk.
This study is the Prospective, Randomized, Controlled, Multi-center Study of Isolated SAVR in Low Risk AS Patients (The AMETHYST trial). Patients will be randomized 1:1 to receive either SAVR or transcatheter heart valve replacement (TAVR) with a commercially available surgical and transcatheter bioprosthetic valves. The aim of this study was to assess the non-inferiority of SAVR compared with TAVR for the combined endpoints of death from any cause, stroke and rehospitalization (hospitalization related to biological valves or procedures or heart failure) at 1 year postoperatively. Patients will be seen for follow-up visits at discharge, 30 days, and annually through 10 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All study participants must meet the following inclusion criteria 1. Severe, calcific aortic stenosis with the following criteria:
AND 2. class ≥ II OR Exercisee test that demonstrates a limited exercise capacity, abnormal blood pressure response, or arrhythmia OR Asymptomatic patients with \<50%
Exclusion Criteria:
Candidates will be excluded from the study if any of the following conditions are present:
Complex coronary artery disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference
Procedure: surgical aortic valve replacement
Transcatheter aortic valve replacement (TAVR) using the device available in Japan in facilities approved to perform TAVR.
Procedure: Transcatheter aortic valve replacement
SAVR
TAVR
Composite endpoint of all-cause mortality, all stroke, and rehospitalization (valve-related or procedure-related and including heart failure)
Time frame: at 1 year post procedure
the rate of all-cause mortality or disabling stroke
Time frame: at one year
the rate of all-cause mortality
Time frame: at one year
the rate of all stroke
Time frame: at one year
the rate of disabling stroke
Time frame: at one year
the rate of rehospitalization (valve-related or procedure-related and including heart failure)
Time frame: at one year
the rate of new bundle branch block or new pacemaker implantation
Time frame: at one year
the rate of new onset of atrial fibrillation
Time frame: at 30 days
the rate of life-threatening bleeding
Time frame: at one year
the rate of occurrence of perivalvular regurgitation ≥ mild by echocardiography
Time frame: at one year
Quality of life as assessed by KCCQ
Time frame: at one year
Quality of life as assessed by EQ-5D-5L
Time frame: at one year
the rate of prosthetic valve endocarditis
Time frame: at one year
the rate of prosthetic valve thrombosis
Time frame: at one year
the rate of valve-related dysfunction requiring repeat procedure
Time frame: at one year
All cause mortality
Time frame: at 30 days
The rate of all stroke (disabling and nondisabling)
Time frame: at 30 days
The rate of Rehospitalization (valve-related or procedure-related and including heart failure)
Time frame: at 30 days
All cause mortality or all stroke
Time frame: at one year
All cause mortality or disabling stroke
Time frame: at 30 days
The rate of vascular complications (major)
Time frame: at 30 days and one year
The rate of Bleeding complications (life threatening, disabling or major)
Time frame: at 30 days
The rate of myocardial infarction
Time frame: at 30 days and one year
The rate of acute kidney injury
Time frame: at 30 days
the rate of new bundle branch block or new pacemaker implantation
Time frame: at 30 days
the rate of occurrence of perivalvular regurgitation ≥ mild by echocardiography
Time frame: at 30 days
The rate of coronary obstruction requiring intervention
Time frame: at 30 days and one year
New York Heart Association class
NYHA Classification criteria: Class I: Subjects with cardiac disease but without resulting limitations of physical activity Class II: Subjects with cardiac disease resulting in slight limitation of physical activity Class III: Subjects with cardiac disease resulting in marked limitation of physical activity Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort
Time frame: at 30 days and one year
Six-minute walk test
Time frame: at 30 days and one year
The length of postoperative ICU stay
Time frame: up to one year
Discharge location
* Home \[including return to pre-admission facilities (excluding hospitals)\] * Other hospital \[excluding rehabilitation hospital\] * Rehabilitation hospital * Death * Other
Time frame: up to one year
Health status as evaluated by Quality of Life questionnaires (KCCQ)
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. This instrument was developed and validated by John Spertus. John is Director of Cardiovascular Education and Outcomes Research at the Mid America Heart Institute, and he is also a Professor of Medicine at the University of Missouri - Kansas City. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. For brevity, only the performance characteristics of the overall summary score are presented in this discussion.
Time frame: at 30 days
Health status as evaluated by Quality of Life questionnaires (EQ-5D-5L)
EQ-5D-5L: Measures 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that can be converted to utilities using an algorithm. Utilities range from 0 to 1, with 1 representing perfect health, and 0 corresponding to the worst imaginable health state
Time frame: at 30 days
Cognitive function assessed by the MMSE
It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment.
Time frame: at one year
The rate of new onset atrial fibrillation
Time frame: at one year
Endpoints of minimally invasive aortic valve replacement (MICS AVR) vs TAVR
Time frame: at 30 days and one year
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for May 2031, 71 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 71 months is above that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osaka University